| Literature DB >> 33737426 |
Boitumelo Prescilla Letswalo1, Karin Schmid-Zalaudek2, Bianca Brix2, Edna Ngoakoana Matjuda3, Fabian Klosz2, Natalie Obernhumer2, Michael Gaisl2, Godwill Azeh Engwa1, Constance Sewani-Rusike1, Per Morten Fredriksen4, Benedicta Nkeh-Chungag1,3, Nandu Goswami5.
Abstract
OBJECTIVES: Prevalence of child and adolescents' overweight and obesity in low- and middle-income countries has increased dramatically. Simultaneously, the incidence of pre-hypertension/hypertension is also increasing in children, which, in turn, predisposes these children to the risk of cardiovascular disease (CVD) in later life. The present study assessed cardiometabolic risk factors and early indicators of vascular dysfunction in adolescents from a low socio-economic rural area in South Africa.Entities:
Keywords: diabetes & endocrinology; epidemiology; hypertension; paediatric endocrinology; vascular medicine
Mesh:
Year: 2021 PMID: 33737426 PMCID: PMC7978086 DOI: 10.1136/bmjopen-2020-042955
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1STROBE statement for study participation. BMI, body mass index; STROBE, Strengthening the Reporting of Observational Studies in Epidemiology.
Anthropometric and haemodynamic parameters in lean and overweight/obese adolescents classified using hypertension
| Lean | Overweight/obese | Total | |||||
| NT | 113 (72.0%) | 29 (38.7%) | 142 (61.2%) | ||||
| Pre-HT | 22 (14.0%) | 14 (18.7%) | 36 (15.5%) | ||||
| HT | 22 (14.0%) | 32 (42.7%) | 54 (23.3%) | ||||
| ♀:♂ | |||||||
| Sex: female/male | 86/27 | 35/9 | 25/4 | 36/10 | 182/50 | ||
| Age | 14.4 (1.0) | 14.3 (1.0) | 14.7 (1.0) | 14.2 (0.9) | |||
| Anthropometric data | Mean (±SD) | Mean (±SD) | Mean (±SD) | Mean (±SD) | p (BP) | p (O/O) | Sex |
| Neck circumference | 29.6 (1.9) | 29.7 (1.8) | 32.34 (2.0) | 32.1 (2.1) | 0.99 | 0.00 | ♀ < ♂** |
| Mid upper arm circumference | 24.3 (2.3) | 24.4 (2.4) | 29.5 (3.2) | 30.5 (3.2) | 0.11 | 0.00 | |
| Waist circumference | 66.9 (5.2) | 69.0 (5.9) | 82.3 (7.7) | 83.9 (8.4) | 0.05 | 0.00 | |
| Hip circumference | 85.9 (5.9) | 87.7 (8.9) | 105.5 (9.4) | 105.7 (9.6) | 0.37 | 0.00 | ♀ > ♂ |
| Thigh circumference | 44.5 (4.5) | 46.1 (4.6) | 56.2 (6.7) | 58.0 (5.8) | 0.02 | 0.00 | |
| Calf circumference | 31.4 (2.8) | 31.8 (3.1) | 38.3 (3.8) | 37.8 (3.0) | 0.95 | 0.00 | |
| Ankle circumference | 22.4 (1.8) | 22.4 (1.5) | 25.2 (2.4) | 24.4 (1.9) | 0.15 | 0.00 | ♀ < ♂* |
| WHtR | 0.42 (0.03) | 0.44 (0.04) | 0.51 (0.05) | 0.53 (0.05) | 0.00 | 0.00 | |
| Fat (%) | 19.7 (6.4) | 21.2 (6.9) | 34.3 (5.8) | 34.4 (6.4) | 0.39 | 0.00 | ♀ > ♂** |
| BMI (kg/m2) | 19.3 (1.8) | 19.9 (2.0) | 27.6 (3.4) | 27.8 (3.3) | 0.28 | 0.00 | |
| BMI percentile | 45.0 (22.7) | 52.7 (21.7) | 93.0 (4.0) | 94.3 (3.9) | 0.11 | 0.00 | |
| Haemodynamic data | |||||||
| SBP (mm Hg) | 109 (8.3) | 122 (9.8) | 114 (7.1) | 128 (10.8) | – | 0.00 | |
| DBP (mm Hg) | 68 (6.1) | 80 (5.5) | 70 (4.1) | 79 (8.4) | – | 0.00 | ♀ > ♂* |
| MAP (mm Hg) | 82 (5.8) | 94 (4.6) | 84 (3.9) | 95 (6.7) | – | 0.00 | |
| HR (Hz) | 83 (13.9) | 88 (14.2) | 82 (9.5) | 87 (13.8) | – | 0.93 | ♀ > ♂* |
| PWV (m/s) | 6.25 (0.78) | 6.41 (0.83) | 6.37 (1.07) | 6.22 (0.89) | 0.94 | 0.77 | ♀ < ♂** |
Classification of normotensive (NT) and (pre-)hypertensive (HT) based on mean systolic and diastolic blood pressure (<90th/>90th) percentiles, respectively. Symbols (♀, ♂) indicate significant sex differences in the given parameters (* p<0.05, ** p<0.01).
BMI, body mass index; DBP, diastolic blood pressure; Fat%, total body fat; HR, heart rate; MAP, mean arterial pressure; p (BP), main effect for pre-hypertension/hypertension in a two-way; p (O/O), main effect for overweight/obesity ANOVA; PWV, pulse wave velocity; SBP, systolic blood pressure; WHtR, waist to height ratio.
Lipid and glucose metabolism in lean and overweight/obese adolescents based on hypertension
| Lean | Overweight/obese | p (BP) | p (O/O) | |||
| NT | HT | NT | HT | |||
| TG (mmol/L) | 0.77 (0.21), 99 | 0.81 (0.26), 40 | 0.87 (0.33), 25 | 1.14 (0.55), 35 | 0.012 | |
| FG (mmol/L) | 4.72 (0.43), 100 | 4.93 (0.52), 40 | 4.67 (0.56), 26 | 4.76 (0.46), 36 | 0.039 | 0.133 |
| TC (mmol/L) | 3.59 (0.81), 99 | 3.77 (0.90), 40 | 3.80 (0.80), 25 | 3.97 (0.79), 35 | 0.187 | 0.124 |
| HDL-c (mmol/L) | 1.20 (0.53), 51 | 1.15 (0.38), 19 | 1.49 (1.7), 12 | 1.42 (0.73), 16 | 0.728 | 0.117 |
| NEFA (mmol/L) | 33.3 (19.6), 49 | 33.9 (18.1), 17 | 23.5 (19.1), 12 | 33.0 (17.2), 17 | 0.257 | 0.234 |
| NO (μg/mL) | 2.66 (1.1), 53 | 2.31 (0.75), 19 | 3.18 (1.4), 13 | 2.74 (1.5), 18 | 0.134 | 0.230 |
| ADMA (μg/mL) | 1.50 (0.32), 74 | 1.46 (0.30), 24 | 1.34 (0.34), 17 | 1.46 (0.32), 22 | 0.604 | 0.220 |
| Insulin (IU/L) | 22.7 (19.3), 73 | 26.7 (30.9), 24 | 30.8 (40.9), 15 | 40.4 (40.1), 21 | 0.178 | 0.244 |
| HOMA-IR | 2.28 (1.3), 57 | 2.41 (1.9), 22 | 2.31 (1.8), 12 | 2.23 (1.2), 15 | 0.856 | 0.985 |
P values indicate effects contributable either to overweight/obesity (p (O/O)) or pre-hypertension/hypertension (p (BP)) or both; values displayed are means (±SD) and available n.
ADMA, asymmetric dimethylarginine; FG, fasting glucose; HDL-c, high density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment - insulin resistance; HT, pre-hypertension/hypertension; NEFA, non-esterified free fatty acids; NO, nitric oxide; NT, normotensive; TC, total cholesterol; TG, triglycerides.
Criteria for cardiometabolic syndrome, insulin resistance and parameters of vascular functioning
| Criteria | |||
| Central obesity | WC < 90th pc | WC >90th pc | n |
| 205 (89.9%) | 23 (10.1%) | 228 | |
| Pre-HT/HT | BP < 90th pc | BP >90th pc | |
| 142 (61.7%) | 88 (38.3%) | 230 | |
| Hypertriglyceridaemia | TG <110 mg/dL | TG >110 mg/dL | |
| 179 (89.9%) | 20 (10.1%) | 199 | |
| Impaired glucose | FG <110 mg/dL | FG >110 mg/dL | |
| 196 (97.0%) | 6 (3.0%) | 202 | |
| Low HDL-c | HDL >40 mg/dL | HDL ≤40 mg/dL | |
| 43 (43.9%) | 55 (56.1%) | 98 | |
| Risk factors combined | WC >90th pc, BP >90th pc, TG >110 mg/dL, FG >100 mg/dL, HDL ≤40 mg/dL | ||
| 1 criteria | 41/90 (45.6%) | ||
| 2 criteria | 18/90 (20.0%) | ||
| ≥3 criteria | 7/90 (7.8%) | ||
| HOMA-IR | HOMA-IR <2.0 | HOMA-IR >2.0 | 106 |
| 57 (53.8%) | 49 (46.2%) | ||
| | 137 | ||
| 100 (73.0%) | 37 (27.0%) | ||
| ▼ | ▼ | ||
| Mean (±SD) | Mean (±SD) | P value | |
| DBP | 72 (±7.3) | 75 (±7.6) | 0.038 |
| PWV | 6.10 (±0.78) | 6.52 (±0.97) | 0.009 |
| NO | 2.79 (±1.2) | 2.30 (±1.0) | 0.076 |
| | 228 | ||
| 169 (74.1%) | 59 (25.9%) | ||
| ▼ | ▼ | ||
| Mean (±SD) | Mean (±SD) | P value | |
| SBP | 114 (12.0) | 119 (11.2) | 0.005** |
| ADMA | 1.44 (0.30) | 1.57 (0.37) | 0.057 |
Mean (±SD) of parameters comparing adolescents with PWV < or > the 50th percentile. * p<0.05, **p<0.01
ADMA, asymmetric dimethylarginine; DBP, diastolic blood pressure; FG, fasting glucose; HDL-c, high density lipoprotein cholesterol; HOMA-IR, homoeostasis model assessment index; HR, heart rate; MAP, mean arterial pressure; NO, nitric oxide; pc, percentile; Pre-HT/HT, pre-hypertension/hypertension; PWV, pulse wave velocity; SBP, systolic blood pressure; TG, triglycerides; WC, waist circumference.
Summary of the multiple linear regression analysis to predict PWV
| Variable | B | 95% CI | SE (B) | β | t | P value |
| Constant | 3.159 | 1.54 to 4.85 | 0.837 | 3.19 | 0.001 | |
| ADMA (μg/mL) | 0.572 | 0.12 to 1.03 | 0.230 | 0.210 | 2.49 | 0.014 |
| SBP (mm HG) | 0.023 | 0.01 to 0.04 | 0.007 | 0.288 | 3.47 | 0.001 |
| TG (mmol/L | −0.546 | −0.97 to −0.12 | 0.218 | −0.214 | −2.51 | 0.013 |
| 0.421 | 0.178 | 0.157 | 8.781 | 0.001 |
Multiple linear regression conducted to predict PWV (predictors excluded from model: age, BMI, fasting glucose, total cholesterol).
ADMA, asymmetric dimethylarginine; BMI, body mass index; PWV, pulse wave velocity; SBP, systolic blood pressure; TG, triglycerides.